source
- Merck's efinopegdutide shows strong MASH resolution in phase 2b trialMerck & Co. reported results from a phase 2b trial (MK-6024-013) evaluating efinopegdutide, a GLP-1 and glucagon receptor co-agonist, in patients with metabolic dysfunction-associated steatohepatit…
- Lilly's oral GLP-1 pill Foundayo reduces sleep apnea events in late-stage trialsIn two late-stage trials, Eli Lilly’s oral GLP‑1 pill Foundayo lowered the apnea‑hypopnea index by an average of 17.8 events per hour, compared with a 4.5‑event reduction for patients on placebo.…